Safety and Tolerability and Efficacy of LCZ696 in Japanese Hypertensive Patients With Renal Dysfunction: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Safety and Tolerability and Efficacy of LCZ696 in Japanese Hypertensive Patients With Renal Dysfunction (NCT01593787), a non-randomized phase 3 study. The primary outcome is Percentage of Participants With Reported Adverse Events (Total Adverse Events, Serious Adverse Events and Death).

2. Clinical Question

The central question is descriptive: what safety events were recorded during treatment, and what blood-pressure outcomes were planned for assessment? The primary endpoint concerns adverse events rather than a comparison of treatments. The listed secondary outcomes include change from baseline in mean sitting systolic and diastolic blood pressure at week 8, blood-pressure control, and successful response rates.

The study does not establish a treatment effect relative to placebo or another active treatment. Participants began on the same starting dose, but the record describes dose escalation under specified conditions. As a result, dose groups reflect treatment received during a changing treatment course, not randomly assigned groups. The registry record does not report numerical results for the blood-pressure outcomes, so their magnitude and precision cannot be assessed from the information recorded.

3. Trial Design

This was a phase 3, multi-center, open-label study of LCZ696 in Japanese hypertensive patients with renal dysfunction. It was non-randomized and used a single-group model. The registry record lists enrollment of 32 and an eight-week treatment period. The study status is completed.

All participants were started on LCZ696 100 mg once daily on day 1. The record describes escalation to LCZ696 200 mg for participants who did not achieve the specified mean sitting diastolic and systolic blood-pressure targets at or after week 2 and had no signs of safety concerns at specified visits. It also describes a 400 mg group for participants who had received 200 mg, did not achieve the targets at or after week 4, and had no safety concerns. The registry text describing that dose increase is incomplete, so further detail about the escalation is not reported in the registry record.

Open-label means that treatment masking was absent. Because allocation was non-randomized and there was no separate control group, observed outcomes across dose labels should not be read as comparisons between equivalent treatment arms. Participants could contribute to different dose categories as treatment changed; the record specifies that adverse-event analyses were grouped by actual treatment at the relevant time, while other safety analyses used maximum treatment. These distinctions matter when interpreting denominators.

The study listed eight outcome measures, including the primary adverse-event measure and secondary blood-pressure outcomes. Numerical blood-pressure results and a statistical analysis plan are not reported in the registry record. The record lists the study start as 2012-05 and primary completion as 2013-03.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: Safety Set: This set included all participants who received at least one dose of LCZ696. AE analysis was determined by actual treatment, i.e. the LCZ696 dose on the day in which the corresponding summary was targeting. Other safety analysis was determined by the maximum treatment.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Percentage of Participants With Reported Adverse Events (Total Adverse Events, Serious Adverse Events and Death), measured over 8 weeks.

The primary endpoint is the percentage of participants with reported adverse events, serious adverse events, and death over eight weeks. These categories address different aspects of safety: total adverse events capture events recorded during treatment, serious adverse events identify events classified as serious, and death is a separate outcome. Reporting them separately helps readers distinguish a broad event count from more severe outcomes.

The registry record describes the safety set as participants who received at least one dose of LCZ696. It also explains that adverse-event analysis was determined by actual treatment—the LCZ696 dose on the day relevant to the summary—while other safety analyses used maximum treatment. This means the group labels and denominators should be interpreted in light of how exposure was assigned for each safety summary.

The posted results include event counts for the LCZ 100 mg, LCZ 200 mg, LCZ 400 mg, and Total LCZ696 entries. They report zero serious adverse events in the listed groups. The death entries do not contain numerical counts. The record gives counts rather than percentages in these entries, and no percentage estimates or uncertainty intervals are reported in the registry record.

Safety endpoints are useful for describing events observed during a study, but a single-group study cannot determine how those events compare with what would have occurred under a different treatment. The endpoint therefore supports a descriptive reading of recorded safety, not a causal comparison.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

What does a percentage endpoint describe?

In general, a percentage endpoint expresses the number of participants meeting a defined event criterion relative to an eligible group. It can be easier to interpret than an event count alone when groups differ in size, but it depends on a clearly defined denominator and event definition. The registry record labels the primary outcome as a percentage of participants, while the posted entries give counts and at-risk denominators. No calculated percentages or confidence intervals are reported in the registry record.

In general, an uncertainty interval describes a range of values compatible with the data under a specified statistical method. It communicates how precisely an estimate is determined; it does not remove bias from study design or establish causation. The registry record does not report uncertainty intervals for the safety results. With event counts this small, any estimate would need to be interpreted cautiously, but no new estimates can be derived from the registry information alone.

Why do the dose groups need careful interpretation?

In general, random assignment helps balance measured and unmeasured characteristics across treatment groups. This study was non-randomized and single-group, so its dose categories were not formed as randomized comparisons. Participants started at 100 mg and some could move to higher doses under specified conditions involving blood-pressure targets and safety. Those who reached a higher dose may therefore differ from those who remained at a lower dose, including because of response and tolerability.

The record specifies two exposure definitions for safety: actual treatment at the time relevant to an adverse-event summary, and maximum treatment for other safety summaries. These definitions can produce different group membership and denominators. The dose entries should be read as exposure summaries under those rules, not as independent arms with comparable baseline characteristics. The total entry should likewise be read according to its own reported denominator, not constructed by adding dose entries.

What can a zero event count tell a reader?

In general, a zero observed count means that no events of the specified type were recorded in the stated analysis group. It does not prove that the underlying event risk is zero. The amount of information depends on the size and follow-up of the group, the completeness of event ascertainment, and the analysis definition. Here, zero serious adverse events are reported in each listed group, but the registry record does not provide uncertainty intervals or details sufficient to make a precise comparative assessment.

Death counts are not numerically reported in the entries. This is different from a reported zero. A missing value cannot be interpreted as either no deaths or a particular death frequency. The endpoint description includes death, but the posted group information does not provide numerical death counts.

What is the role of the blood-pressure outcomes?

In general, change from baseline measures the difference between a participant's starting value and a later measurement. A group summary can describe the average change, while a control-rate outcome describes the proportion meeting a stated target. These measure different features: average change reflects the distribution of measurements, while a threshold outcome depends on whether values cross a specified boundary.

The registry lists change in mean sitting systolic and diastolic blood pressure at week 8, along with blood-pressure control and response outcomes. However, numerical results for these outcomes are not reported in the registry record. The escalation criteria include mean sitting diastolic blood pressure below 80 mmHg and mean sitting systolic blood pressure below 130 mmHg. Those thresholds describe the treatment decision criteria in the record; they do not supply the missing outcome results.

What statistical analysis was planned?

The statistical analysis plan, including tests, adjustment methods, and handling of repeated measurements, is not reported in the registry record. The record also does not report an interim-analysis plan or a sample-size justification. Without these details, it is not possible to assess whether the endpoint analyses followed a prespecified model, how missing observations were treated, or what inferential claims were intended.

In general, descriptive event counts and comparative statistical tests answer different questions. Counts describe what was recorded; a test or model may estimate a contrast and quantify uncertainty under explicit assumptions. Since there is no randomized comparator and no reported inferential analysis for the results described, the safety entries are best interpreted descriptively. No observed power claim or treatment-effect estimate follows from these counts alone.

10. Multiplicity, Missing Data and Analysis Populations

The registry record lists a primary safety outcome and multiple secondary outcomes, including blood-pressure change, control, and response. It does not report a multiplicity strategy for interpreting several outcomes or for controlling the chance of false-positive findings across multiple tests. Numerical results and inferential tests for the secondary outcomes are also not reported in the registry record. Without those details, the role of any nominal statistical significance cannot be assessed.

Missing-data methods are not reported in the registry record. The record does not describe how absent blood-pressure measurements, withdrawals, or incomplete follow-up were handled, nor does it provide outcome-specific denominators for the unreported blood-pressure results. It is therefore not possible to determine whether the analyses used all enrolled participants, only participants with available measurements, or another analysis population for those endpoints.

The safety population is described as participants who received at least one dose of LCZ696. For adverse events, the group was based on the dose received on the day relevant to the summary; for other safety analyses, it was based on maximum treatment. These definitions should not be assumed to apply to the blood-pressure outcomes, because their analysis population is not reported in the registry record.

The record does not report a statistical analysis plan, an interim-analysis plan, or a sample-size justification. It also does not explain whether missing outcomes were imputed or whether sensitivity analyses were conducted. These gaps limit assessment of prespecification and robustness. They do not change the descriptive counts that are reported, but they restrict conclusions about precision, endpoint selection, and the effect of incomplete data.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent non-serious adverse event terms

The serious-adverse-event entries report 0 events in the LCZ 100 mg group among 32 at risk, 0 in the LCZ 200 mg group among 26 at risk, 0 in the LCZ 400 mg group among 18 at risk, and 0 in the Total LCZ696 group among 32 at risk. These are the reported counts, not estimates of zero underlying risk. The record does not provide confidence intervals or comparative tests for these figures.

Other adverse events are reported as counts: 5 among 32 at risk for LCZ 100 mg, 0 among 26 for LCZ 200 mg, 5 among 18 for LCZ 400 mg, and 9 among 32 for Total LCZ696. The entry denominators follow the registry's exposure definitions. In particular, adverse-event summaries use actual treatment at the relevant time. The dose groups are therefore not independent randomized arms, and the entries should not be combined or compared as if they were.

Death is named as part of the primary endpoint, but numerical death counts are not reported in the registry record. That absence is not a reported zero. The counts describe events recorded during the specified treatment period; they do not establish whether treatment caused an event or how the results would compare with another treatment.

12. What the Result Does, and Does Not, Mean

The record documents a completed, open-label, non-randomized, single-group study of LCZ696 in Japanese hypertensive patients with renal dysfunction. It describes treatment beginning at 100 mg once daily, with escalation conditions involving blood-pressure targets and safety. The primary endpoint concerns adverse events, serious adverse events, and death over eight weeks. The posted safety results report counts for other adverse events and zero serious adverse events in each listed entry.

These observations are descriptive. There is no randomized control group against which to estimate a comparative effect, and treatment dose was not assigned randomly. Differences among the dose-labelled entries cannot be interpreted as dose effects because participants could reach higher doses according to response and safety criteria. The counts also do not establish that LCZ696 caused any particular event.

The record does not report numerical death counts, blood-pressure outcome results, or uncertainty intervals. Thus it does not permit a precise account of the incidence of death, the size of blood-pressure changes, or the precision of any treatment effect. The absence of numerical results is not evidence of no events or no change.

In general, a small descriptive study can identify what was recorded in its participants, while providing limited information about uncommon events or comparisons with alternative care. The posted information should be read within that scope. It does not establish efficacy or comparative safety, and it does not support medical advice about treatment choices.

13. Why This Trial Matters Statistically

This trial is statistically instructive because its treatment pathway makes the meaning of a dose label important. Participants started on 100 mg, and escalation depended on blood-pressure response and safety conditions. Consequently, dose-based summaries do not function like randomized arms. Understanding how participants entered each exposure category is essential before interpreting event counts.

The record also illustrates why a denominator is part of a result rather than a minor detail. It defines adverse-event grouping by actual treatment at the time relevant to the summary and other safety grouping by maximum treatment. This creates different exposure-based summaries, and the total entry has its own reported denominator. Treating the entries as mutually exclusive groups or adding their counts would misrepresent the record.

A second lesson is the distinction between zero and missing. Zero serious adverse events are explicitly reported in the entries. Numerical death counts are absent, which is not the same as a reported zero. Likewise, blood-pressure outcomes are named but their numerical results are not reported. Statistical interpretation must preserve these differences rather than fill gaps with assumptions.

Finally, the trial shows the limits of descriptive safety data without a randomized comparator and reported uncertainty estimates. The event counts can be read as observations in the recorded groups, but they cannot determine comparative effects or establish causality. Statistical conclusions depend not only on a number, but on how participants were assigned, how the endpoint was defined, and what information is missing.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The main design limitation is the absence of randomization and a separate control group. The study is described as open-label, non-randomized, and single-group. As a result, comparisons between dose entries are vulnerable to differences in participant characteristics and treatment history, and there is no concurrent comparator for interpreting event counts or blood-pressure outcomes.

Dose escalation was conditional on blood-pressure targets and safety. This makes the dose categories dependent on events and responses during treatment. The record's distinction between actual dose for adverse-event summaries and maximum dose for other safety summaries further affects group membership. These categories should not be treated as fixed, parallel groups.

The registry record does not report numerical blood-pressure outcomes, numerical death counts, confidence intervals, or detailed statistical analyses. It does not report the statistical analysis plan, missing-data methods, or a sample-size justification. The description of the 400 mg escalation is incomplete. These omissions limit assessment of outcome magnitude, precision, analysis choices, and completeness of reporting.

Enrollment was 32 and the treatment period was eight weeks. The record therefore describes a limited observation period and does not provide evidence about longer-term outcomes. No conclusions about the frequency of uncommon events or comparative effects can be drawn from the reported descriptive counts alone. These limitations concern what the registry record can establish; they do not imply that unreported outcomes were favorable or unfavorable.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Safety and Tolerability and Efficacy of LCZ696 in Japanese Hypertensive Patients With Renal Dysfunction — NCT01593787.
• Registry record last updated 2015-08-13; status last verified 2015-08.
• Results first posted 2015-08-13.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

NCT01593787 is a completed phase 3, multi-center, open-label, non-randomized, single-group study of LCZ696 in Japanese hypertensive patients with renal dysfunction. Enrollment was 32, and the treatment period was eight weeks. Participants started on LCZ696 100 mg once daily, with dose escalation described under blood-pressure and safety conditions.

The primary outcome concerns the percentage of participants with adverse events, serious adverse events, and death. The posted results give dose-based safety counts, including zero reported serious adverse events in each listed entry. Numerical death counts are not reported. Secondary outcomes include blood-pressure change and control, but numerical results are not reported in the registry record.

Because treatment was not randomized and there was no control group, dose entries are descriptive rather than like-for-like comparisons. The record does not report uncertainty intervals, a statistical analysis plan, missing-data methods, or a sample-size justification.